Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Conference, Product/Service, Trade Show

Horizon to Highlight Novel Insights in Gout Care During the American College of Rheumatology Convergence 2022

Horizon Therapeutics plc (Nasdaq: HZNP) today announced plans for a series of data presentations on its marketed and pipeline medicines, with a focus on continued efforts to advance the understanding and care of uncontrolled gout, during the American College of Rheumatology Convergence 2022 to be hosted in Philadelphia and online, Nov. 10-14, 2022.

Key results from the MIRROR randomized controlled trial will be presented as part of the American College of Rheumatology Convergence 2022 plenary session:

Poster presentations on KRYSTEXXA will include:

Additional presentations on the impact of uncontrolled gout will include:

Horizon will also present new insights on an emerging pipeline program:



KRYSTEXXA® (pegloticase) is indicated for the treatment of chronic gout in adult patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.





Gout Flares: An increase in gout flares is frequently observed upon initiation of anti-hyperuricemic therapy, including KRYSTEXXA. Gout flare prophylaxis with a non-steroidal anti-inflammatory drug (NSAID) or colchicine is recommended starting at least 1 week before initiation of KRYSTEXXA therapy and lasting at least 6 months, unless medically contraindicated or not tolerated.

Congestive Heart Failure: KRYSTEXXA has not been formally studied in patients with congestive heart failure, but some patients in the pre-marketing placebo-controlled clinical trials experienced exacerbation. Caution should be exercised in patients who have congestive heart failure and patients should be closely monitored following infusion.


The most commonly reported adverse reactions (?5%) are:

Please see Full Prescribing Information, including Boxed Warning.

About Horizon

Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

These press releases may also interest you

at 16:30
PriceSmart, Inc. announced today that Sherry Bahrambeygui will be resigning as Chief Executive Officer, effective February 3, 2023, the date of the Company's annual stockholder meeting, in order to pursue new professional and philanthropic...

at 16:24
Gender-based violence remains an ongoing problem in Alberta, and across Canada. One measure of this situation is that gender-based violence crisis hotlines in Alberta saw a 50 per cent or higher increase in the number of calls over the past year. Now...

at 16:20
TPG RE Finance Trust, Inc. ("TRTX" or the "Company") today announced the Company's Board of Directors declared a cash dividend of $0.3906 per share of 6.25% Series C Cumulative Redeemable Preferred Stock (the "Series C Preferred Stock") for the...

at 16:20
Ares Dynamic Credit Allocation Fund, Inc. (the "Fund") announced today the declaration of its distribution for the month of December 2022 of $0.1025 per common share, payable as noted below. The following dates apply to the declared distribution:...

at 16:15
Sentage Holdings Inc. (the "Company", "we", "our") , is a holding company incorporated in the Cayman Islands with no material operations of its own. Through its China-based operating entities, the Company offers a comprehensive range of financial...

at 16:15
The "Soy Food Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to  ResearchAndMarkets.com's offering. The global soy food market reached a value of US$ 44.7 Billion in 2021. Looking...

News published on 19 september 2022 at 08:10 and distributed by: